1. Home
  2. PRTC vs SAR Comparison

PRTC vs SAR Comparison

Compare PRTC & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • SAR
  • Stock Information
  • Founded
  • PRTC 2015
  • SAR 2007
  • Country
  • PRTC United States
  • SAR United States
  • Employees
  • PRTC N/A
  • SAR N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • SAR Investment Managers
  • Sector
  • PRTC Health Care
  • SAR Finance
  • Exchange
  • PRTC Nasdaq
  • SAR Nasdaq
  • Market Cap
  • PRTC 413.5M
  • SAR 388.3M
  • IPO Year
  • PRTC N/A
  • SAR 2007
  • Fundamental
  • Price
  • PRTC $19.07
  • SAR $25.15
  • Analyst Decision
  • PRTC Buy
  • SAR Hold
  • Analyst Count
  • PRTC 1
  • SAR 4
  • Target Price
  • PRTC $45.00
  • SAR $24.75
  • AVG Volume (30 Days)
  • PRTC 3.4K
  • SAR 135.3K
  • Earning Date
  • PRTC 08-27-2025
  • SAR 07-08-2025
  • Dividend Yield
  • PRTC N/A
  • SAR 11.91%
  • EPS Growth
  • PRTC N/A
  • SAR 105.87
  • EPS
  • PRTC 0.21
  • SAR 2.47
  • Revenue
  • PRTC $4,828,000.00
  • SAR $142,495,705.00
  • Revenue This Year
  • PRTC $35.98
  • SAR N/A
  • Revenue Next Year
  • PRTC $115.38
  • SAR $1.25
  • P/E Ratio
  • PRTC $8.64
  • SAR $10.19
  • Revenue Growth
  • PRTC 44.98
  • SAR N/A
  • 52 Week Low
  • PRTC $13.30
  • SAR $21.10
  • 52 Week High
  • PRTC $25.00
  • SAR $26.49
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 57.26
  • SAR 53.90
  • Support Level
  • PRTC $18.16
  • SAR $24.80
  • Resistance Level
  • PRTC $19.60
  • SAR $25.60
  • Average True Range (ATR)
  • PRTC 0.43
  • SAR 0.40
  • MACD
  • PRTC 0.10
  • SAR 0.01
  • Stochastic Oscillator
  • PRTC 69.77
  • SAR 71.70

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

Share on Social Networks: